NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination last week proposing that it end coverage of Myriad Genetics' rheumatoid arthritis test Vectra DA.

Explaining its reasoning for ending coverage of Vectra DA, Palmetto cited recent studies that raise questions as to whether the test is effective in assessing disease activity in RA patients. The draft LCD also noted the lack of prospective clinical utility data on the test and the fact that it is not included in the 2015 American College of Rheumatology treatment guidelines.

Get the full story with 360Dx Premium

Only $95 for the first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.